IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

IDWeek Highlights |Dr. Mei Zeng: Racing Against Time! Developing the Predictive Models for Early Identification of Severe Infections in Newborns

2023.11.27
Half of all global child deaths under the age of 5 are caused by infections, and half of all sepsis patients worldwide are children, especially newborns. These alarming statistics highlight the significant challenge of infection treatment in pediatric clinical practice. At the recent IDWeek 2023 congress in the United States, a predictive model for severe infection in infants under 90 days of age, based on clinical data and inflammatory biomarkers, was reported. This predictive model may aid in the early identification of newborns at high risk of severe infection, allowing timely clinical intervention to reduce the risk of disease progression. Dr. Mei Zeng from the Children's Hospital of Fudan University/National Children's Medical Center provides an introduction and commentary on this research.
IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

IDWeek Highlights |Dr. Yi-min Wang: Bundle Diagnosis for VAP Can Reduce Misdiagnosis and Antibiotic Overuse

2023.11.27
Precision treatment starts with accurate diagnosis. The clinical diagnosis of ventilator-associated pneumonia (VAP) is challenging, with a high misdiagnosis rate leading to excessive antibiotic use. At the recent 2023 IDWeek conference in the United States, a clinical trial was reported that utilized a bundled approach to VAP diagnosis and management. The results showed that it is safe and significantly reduces the respiratory culture positivity rate and antibiotic usage. Below, Professor Wang Yimin and his team from the China-Japan Friendship Hospital introduce and comment on this study.
Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

Dr. Chun-hui Li’s Commentary on a Randomized Controlled Trial of Oral Fosfomycin for Down-Step Therapy in ESBL-E Complicated Urinary Tract Infections

2023.11.27
Carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) have been designated as "urgent priorities" in antibiotic research and development by the WHO. Besides accelerating the development of new drugs, emphasizing the "repurposing" of existing drugs under antimicrobial stewardship (AMS) can help alleviate the threat of resistant bacteria. At the 2023 IDWeek congress, There is a study using oral fosfomycin as a step-down therapy for ESBL-E complicated urinary tract infections (cUTI), as an alternative to intravenous beta-lactam/beta-lactamase inhibitor (BL/BLIS) therapy, achieving non-inferiority results. Dr. Chun-hui Li from Xiangya Hospital, Central South University, introduces and comments on the study as follows.
IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

IDweek2023 | A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial

2023.10.27
IDweek2023A Comprehensive Exploration of At-Home vs. In-Clinic Administration of Cabotegravir and Rilpivirine Long-Acting: An In-depth Analysis of an Implementation Science Trial The approval of the long-acting injectable cabotegravir-rilpivirine in January 2021 marked a significant milestone in the medical realm. This dual-drug regimen has revolutionized the approach to HIV treatment by providing an effective and convenient alternative to daily oral medications. However, the question of how to best optimize access to this therapy in our clinics was an issue that required immediate attention. Consequently, a hypothesis was developed suggesting that cabotegravir-rilpivirine could be safely and effectively administered in a person’s own home, paving the way for an innovative study to test this theory.
IDweek2023 Exploring the Latest Advances in COVID-19 Therapeutics: Insights from Jason C. Gallagher

IDweek2023 Exploring the Latest Advances in COVID-19 Therapeutics: Insights from Jason C. Gallagher

2023.10.27
IDweek2023 Exploring the Latest Advances in COVID-19 Therapeutics: Insights from Jason C. Gallagher In the midst of the ongoing COVID-19 pandemic, researchers and healthcare professionals have been tirelessly working to develop effective therapeutics to combat the virus. In this article, we delve into the latest updates on COVID-19 therapeutics based on a presentation by Jason C. Gallagher, Pharm.D., FIDP, FCCP, FIDSA, BCPS, a Clinical Professor at Temple University. His expertise in the field provides valuable insights into important developments in the treatment of COVID-19.